Top Gap Ups and Downs on Friday: NVO, TM, INFY and More
BeiGene Shares Climb Pre-Bell After FDA Gives Favorable Opinion on Class of Cancer Treatments
BeiGene Announces Board and Committee Structure
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, Including TEVIMBRA, for Treatment of ESCC and Gastric/GEJ Cancers
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use
Beigene (06160.HK) appoints Shalini Sharp as an independent non-executive director.
Beigene announced on September 26th that the board of directors of the company will increase the number of directors from 11 to 12, and appoint Ms. Shalini Sharp as an independent non-executive director to fill the vacancy caused by the increase in the number of board members, effective from September 27, 2024.
